Company: LNAI
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0001731122-25-000037
Chunk: 1

Company: Lunai Bioworks Inc.
Filing Date: 2025-01-07
Form: 8-K
Item: Item 1.01
Chunk 1
---
 investment of not less than $1,000,000, will entitle Renovaro to a two-year exclusive royalty-free license
to Predictive Oncology’s biobank of tumor samples and tumor-specific 3D cell culture models.

There can be no assurance that a definitive merger
agreement or transaction with Predictive Oncology will be executed, or as to the timing of any such agreement or transaction. Renovaro
does not intend to discuss or disclose further developments regarding these discussions unless and until its Board of Directors has approved
a transaction or otherwise determined that further disclosure is appropriate or required by law.

Item 7.01
Regulation FD Disclosure.

On January 6, 2025, the Company issued a press release
announcing that it had entered into a binding letter of intent with Predictive Oncology for Predictive Oncology to be acquired by Renovaro
in exchange for preferred stock of Renovaro, the entire text of which is attached hereto as Exhibit 99.1 and is incorporated by reference
herein. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein
and herein are deemed to be furnished and shall not be deemed to be filed.

Item 9.01
Financial Statements and Exhibits.

  Exhibit No.      Description                                                                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────
          1.1      Letter of Intent between Predictive Oncology and Renovaro.                    
         99.1      Press Release of Renovaro Inc. dated January 6, 2025.                         
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURES